# Immunization With the MAGE-3.A1 Peptide Mixed With the Adjuvant CpG 7909 in Patients With Metastatic Melanoma

> **NCT00145145** · PHASE1,PHASE2 · TERMINATED · sponsor: **Ludwig Institute for Cancer Research** · enrollment: 1 (actual)

## Conditions studied

- Malignant Melanoma

## Interventions

- **BIOLOGICAL:** MAGE-3.A1 peptide and CpG 7909

## Key facts

- **NCT ID:** NCT00145145
- **Lead sponsor:** Ludwig Institute for Cancer Research
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-01-12
- **Primary completion:** 2005-04-07
- **Final completion:** 2008-04-28
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Poor Accrual
- **Last updated:** 2022-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00145145

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00145145, "Immunization With the MAGE-3.A1 Peptide Mixed With the Adjuvant CpG 7909 in Patients With Metastatic Melanoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00145145. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*